The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
345
Sanofi-Aventis Aministrative Office
Bridgewater, New Jersey, United States
Sanofi-Aventis Administrative Office
Laval, Quebec, Canada
Sanofi-Aventis Administrative Office
Prague, Czechia
Sanofi-Aventis Administrative Office
Paris, France
Change from baseline in the number of micturitions per 24 hours
Time frame: at week 12
Changes from baseline in number of urge urinary incontinence episodes, in number of urgency episodes, in number of nocturia episodes, in volume of urine per void
Time frame: at week 12
Safety of SSR240600C
Time frame: at week 12
Quality of life
Time frame: at week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Gouda, Netherlands
Sanofi-Aventis Administrative Office
Porto Salvo, Portugal